Meta Information

ID:denosumab

Name:Denosumab

Schema Version:1.5

Alternate Names

• Prolia
• Xgeva

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

250

High Cost:

500

Cost Type:

monthly

Description:

Prescription drug cost, often covered by insurance for diagnosed osteoporosis.

Summary

Denosumab is a monoclonal antibody that inhibits RANKL, a protein essential for the formation and function of bone-resorbing cells called osteoclasts. By potently suppressing bone breakdown, it significantly increases bone mineral density and reduces the risk of fractures. Its primary healthspan relevance is the prevention of osteoporosis and fragility fractures, a major cause of morbidity, mortality, and loss of independence in older adults.

Purpose

Potent antibody therapy to prevent age-related bone loss and fractures.

Card Summary

A monoclonal antibody that inhibits bone breakdown, significantly increasing bone density and reducing fracture risk.

Drug Class

rankl_inhibitor

Drugs In Class

Empty Array

Impact

Score:

7.2

Justification:

Extremely effective at preventing fractures, a major cause of age-related morbidity and mortality.

Evidence

Grade:

A

Score:

9.5

Justification:

Multiple large, long-term human RCTs and meta-analyses confirm efficacy for fracture prevention.

Safety

Score:

6.5

Justification:

Requires medical supervision; risk of rare serious side effects and rebound fractures upon discontinuation.

Flags

• Discontinuation causes a rapid rebound in bone resorption and a significant increase in fracture risk.
• Requires adequate calcium and vitamin D supplementation to prevent hypocalcemia.
• Rare but serious risks include osteonecrosis of the jaw (ONJ) and atypical femoral fractures.
• May increase the risk of certain infections, particularly skin infections like cellulitis.
• Primarily indicated for individuals with diagnosed osteoporosis or high fracture risk, not general prevention.

Verdict

Highly effective for bone health, but requires a long-term commitment.

Created

2026-04-26T18:31:33.291964Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

subcutaneous_injection

Scope:

• systemic

Indication

Focus:

disease_treatment

Description:

Denosumab is a monoclonal antibody that inhibits RANKL, a protein essential for the formation and function of bone-resorbing cells called osteoclasts. By potently suppressing bone breakdown, it signif...

Typical Protocol

• A 60 mg subcutaneous injection administered once every 6 months by a healthcare professional.